title: Interaction of dual intracellular signaling pathways activated by the melanocortin-3 receptor.
abstract: We undertook these studies to explore the intracellular signaling mechanisms activated by a newly described human brain melanocortin receptor (hMC3R). Hepa cells transfected with the hMC3R gene responded to stimulation with alpha-melanocyte stimulation hormone (alpha-MSH) and adrenocorticotropic hormone (ACTH) with dose-dependent increases in cellular content of cyclic 3',5'-adenosine monophosphate (cAMP) reaching a maximum of over 1500% of control cells at the 10(-8) M dose (EC50 = 10(-11) M). In contrast, the production of [3H]inositol phosphates in cells prelabeled with myo-[2-3H]inositol exhibited a biphasic dose-response curve with increases as high as 155% of basal at 10(-11) M alpha-MSH or ACTH, but beyond that a dose-dependent decrease was observed. The inhibitory component of the dose-response curve could be abolished by pretreatment of transfected cells with the cAMP antagonist (Rp)-adenosine 3',5'-monophosphorothioate (Rp-cAMP) or the protein kinase A inhibitor H-89. Increases in intracellular calcium induced in transfected cells by alpha-MSH in doses ranging from 10(-11) to 10(-7) M could not be observed unless the cells were pretreated with H-89. By replacing the third intracytoplasmic loop of the canine H2-histamine receptor with that of hMC3R the biphasic characteristic of agonist-induced production of [3H]inositol phosphates was conferred to the chimeric receptor. These data indicate that the hMC3R is coupled to both cAMP and inositol phospholipid/Ca(2+)-mediated post-receptor signaling systems and that the latter response is regulated by protein kinase A activity.
authors.affiliation: Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109-4770.
authors.forename: Y
authors.initials: Y
authors.lastname: Konda
authors.forename: I
authors.initials: I
authors.lastname: Gantz
authors.forename: J
authors.initials: J
authors.lastname: DelValle
authors.forename: Y
authors.initials: Y
authors.lastname: Shimoto
authors.forename: H
authors.initials: H
authors.lastname: Miwa
authors.forename: T
authors.initials: T
authors.lastname: Yamada
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D016466:CHO Cells; D002118:Calcium / Q000378:metabolism; D006224:Cricetinae; D000242:Cyclic AMP / Q000096:biosynthesis; D006801:Humans; D007295:Inositol Phosphates / Q000378:metabolism; D007739:L Cells; D051379:Mice; D051381:Rats; D044104:Receptor, Melanocortin, Type 3; D018043:Receptors, Corticotropin / Q000378:metabolism*; D015398:Signal Transduction; D014407:Tumor Cells, Cultured; D000521:alpha-MSH / Q000494:pharmacology
chemical_list: D007295:Inositol Phosphates; D044104:Receptor, Melanocortin, Type 3; D018043:Receptors, Corticotropin; D000521:alpha-MSH; D000324:Adrenocorticotropic Hormone; D000242:Cyclic AMP; D002118:Calcium